RapidAI, a company specializing in deep clinical artificial intelligence (AI) and enterprise imaging, has gained U.S. Food and Drug Administration (FDA) clearance of Aortic Management, a new clinical AI solution.

Aortic Management is part of the company’s Rapid Aortic product, a deep clinical AI solution that aims to transform acute assessment and longitudinal management of aortic disease. RapidAI believes the next-gen AI can reduce cognitive burden on radiologists, inform acute treatment and transfer decisions, and boost longitudinal management.

RapidAI offers clinical info powered by AI to help quickly and accurately identify more aortic aneurysms, dissections, and other anomalies. It also automatically generates critical measurements, produces automated 3D reconstructions of the aorta, and tracks anatomical changes over time.

This way, radiologists can quickly evaluate the aorta with less burden and faster reading times, while letting surgeons and clinicians more effectively monitor patients longitudinally.

Rapid Aortic allows analysis of all CT scans that include the aorta to assist with identifying and tracking pathology from the aortic arch in the chest to the iliacs in the pelvis. It produces guideline-based measurements, including six zonal maximums and 18 landmark metrics. Built-in longitudinal comparisons enable tracking side by side with previous studies, as well.

It’s integrated into the Rapid Edge Cloud, a cloud-based IT platform with on-prem capabilities that ensures continuous service. All modules are integrated into Rapid Navigator Pro, the company’s radiology solution, as well as the Rapid mobile and web apps.

Together, RapidAI said they create a seamless, secure experience across PACS, EHR, and reporting systems, enabling clinicians to access, compare, and act on critical findings without disrupting their workflow.

“This clearance reinforces the depth of our deep clinical AI platform and its growing impact across care teams,” said Karim Karti, CEO of RapidAI. “Rapid Aortic exemplifies how we’re delivering intelligent, workflow-integrated tools that move beyond detection to full patient management. By combining precision, speed, and seamless interoperability, we’re helping health systems improve efficiency, strengthen care coordination, and ultimately enhance outcomes for patients with aortic disease.”

Earlier this year, the company shared a new study that demonstrated the superiority of its stroke imaging tech.